These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 17854663

  • 1. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
    Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY.
    Cancer Genet Cytogenet; 2007 Sep; 177(2):103-7. PubMed ID: 17854663
    [Abstract] [Full Text] [Related]

  • 2. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nistér M, Smits A, Ren ZP.
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [Abstract] [Full Text] [Related]

  • 3. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
    Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C.
    Cancer Genet Cytogenet; 2010 Apr 15; 198(2):126-34. PubMed ID: 20362227
    [Abstract] [Full Text] [Related]

  • 4. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T.
    Clin Cancer Res; 2002 Jan 15; 8(1):196-201. PubMed ID: 11801559
    [Abstract] [Full Text] [Related]

  • 5. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C.
    Neurol India; 2009 Jan 15; 57(5):559-66. PubMed ID: 19934553
    [Abstract] [Full Text] [Related]

  • 6. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
    Hirose T, Ishizawa K, Shimada S.
    Neuropathology; 2010 Dec 15; 30(6):586-96. PubMed ID: 20408960
    [Abstract] [Full Text] [Related]

  • 7. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.
    Zhonghua Zhong Liu Za Zhi; 2011 Oct 15; 33(10):752-8. PubMed ID: 22335907
    [Abstract] [Full Text] [Related]

  • 8. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.
    Brain Res; 2008 Mar 10; 1198():16-20. PubMed ID: 18262501
    [Abstract] [Full Text] [Related]

  • 9. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
    Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW.
    Brain Res Mol Brain Res; 2005 Jun 13; 137(1-2):98-103. PubMed ID: 15950766
    [Abstract] [Full Text] [Related]

  • 10. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2002 Mar 13; 103(3):267-75. PubMed ID: 11907807
    [Abstract] [Full Text] [Related]

  • 11. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K.
    Cancer; 2005 Oct 01; 104(7):1468-77. PubMed ID: 16088966
    [Abstract] [Full Text] [Related]

  • 12. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network.
    Clin Cancer Res; 2007 Dec 01; 13(23):6933-7. PubMed ID: 18056167
    [Abstract] [Full Text] [Related]

  • 13. Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
    Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC.
    Ann Neurol; 2005 Jun 01; 57(6):855-65. PubMed ID: 15929038
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ.
    Clin Cancer Res; 2002 May 01; 8(5):1117-24. PubMed ID: 12006527
    [Abstract] [Full Text] [Related]

  • 15. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.
    Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, Lopes JM, Reis RM.
    Cancer Genet Cytogenet; 2008 Jan 01; 180(1):14-9. PubMed ID: 18068527
    [Abstract] [Full Text] [Related]

  • 16. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients.
    Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, Slomski R.
    Oncol Rep; 2006 Jul 01; 16(1):65-71. PubMed ID: 16786124
    [Abstract] [Full Text] [Related]

  • 17. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2004 Jul 01; 108(1):49-56. PubMed ID: 15118874
    [Abstract] [Full Text] [Related]

  • 18. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, Golanska E, Sikorska B, Liberski PP.
    Clin Neuropathol; 2006 Jul 01; 25(1):18-24. PubMed ID: 16465770
    [Abstract] [Full Text] [Related]

  • 19. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC.
    Neurology; 2006 Jun 13; 66(11):1661-7. PubMed ID: 16769937
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M, Peraud A, Leroch B, Kreth FW.
    Cancer; 2004 Sep 01; 101(5):1028-35. PubMed ID: 15329912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.